Why do Australian dermatologists screen for Strongyloides stercoralis before dupilumab?

Clicks: 21
ID: 328294
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #151 of 412 articles by views in the british journal of dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 412 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
We examined why the majority (86%) of Australian dermatologists screen universally for Strongyloides prior to commencing dupilumab, despite the low seroprevalence of Strongyloides infection (1.4% in our cohort) and absence of cases of hyperinfection across 887 person-years of dupilumab exposure. This work includes an audit of 325 patients prescribed dupilumab for atopic dermatitis and a national survey of Australian dermatologists to determine screening practices. We found that universal screening occurs due to concern regarding the mechanism of action of dupilumab conferring high risk of disseminated Strongyloidiasis, peer practice and lack of screening guidelines. The strongest motivator to change this practice would be the introduction of screening guidelines.
Reference Key
openalex_W7212059007 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal the british journal of dermatology
Year 2026
DOI
10.1093/bjd/ljag382
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.